Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
1 The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsA Long-Term Evaluation), a large double-blind, placebo-controlled trial, recently demonstrated that liraglutide added to standard therapy for a relatively short period of time (3.5-5 years) had a significant reduction in cardiovas-cular events and mortality compared to placebo in high-risk patients (hazard ratio [HR], 0.87
El estudio, publicado este martes en 'Journal of Alzheimer's Disease', sugiere que los pacientes con diabetes tipo 2 que tomaban semaglutida tenan un riesgo significativamente menor de desarrollar demencia en comparacin con otros medicamentos antidiabticos
The non-competitive Fab7F38 could be an important tool for further structural clarification of the existence of different states of GLP-1R
Reducing UV exposure may also help prevent existing pigmentation from being maintained or deepened further
No membership fees, national coverage, and clear timing
US$ 21.23
US$ 27.32
US$ 20.02
US$ 25.42
US$ 29.60
US$ 26.28
US$ 24.04
